Susquehanna Fundamental Investments LLC Takes $668,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Susquehanna Fundamental Investments LLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 88,854 shares of the biotechnology company's stock, valued at approximately $668,000.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the period. Eversept Partners LP increased its position in shares of BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after acquiring an additional 1,444,907 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after acquiring an additional 91,998 shares during the period. Jupiter Asset Management Ltd. lifted its position in BioCryst Pharmaceuticals by 10.1% in the 4th quarter. Jupiter Asset Management Ltd. now owns 1,177,929 shares of the biotechnology company's stock valued at $8,858,000 after acquiring an additional 108,030 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in BioCryst Pharmaceuticals by 6.7% in the 4th quarter. Invesco Ltd. now owns 1,072,600 shares of the biotechnology company's stock worth $8,066,000 after purchasing an additional 67,492 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 23.5 %

Shares of BCRX stock traded up $2.10 on Monday, reaching $11.03. The stock had a trading volume of 24,800,859 shares, compared to its average volume of 2,922,235. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.75 and a 12 month high of $11.48. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -18.08 and a beta of 1.08. The firm's 50-day moving average is $7.74 and its two-hundred day moving average is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27. During the same period last year, the firm earned ($0.17) earnings per share. BioCryst Pharmaceuticals's revenue for the quarter was up 56.8% compared to the same quarter last year. On average, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on BCRX. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Needham & Company LLC reissued a "buy" rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.13.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.